Literature DB >> 20959896

Drug therapy in patients with chronic renal failure.

Bertram Hartmann1, David Czock, Frieder Keller.   

Abstract

BACKGROUND: Roughly 20% of patients in hospital have impaired kidney function. This is frequently overlooked because of the creatinine-blind range in which early stages of renal failure are often hidden. Chronic kidney disease is divided into 5 stages (CKD 1 to 5).
METHODS: Selective literature search.
RESULTS: Methotrexate, enoxaparin and metformin are examples of drugs that should no longer be prescribed if the glomerular filtration rate (GFR) is 60 mL/min or less. With antidiabetic (e.g. glibenclamide), cardiovascular (e.g. atenolol) or anticonvulsive (e.g. gabapentin) drugs, the advice is to use alternative preparations such as gliquidone, metoprolol or carbamazepine which are independent of kidney function. Drug dose adjustment should be considered with antimicrobial (e.g. ampicillin, cefazolin), antiviral (e.g. aciclovir, oseltamivir) and, most recently, also for half of all chemotherapeutic and cytotoxic drugs in patients with impaired kidney function (with e.g. cisplatin, for instance, but not with paclitaxel).
CONCLUSION: Decisions concerning drug dose adjustment must be based on the pharmacokinetics but this is an adequate prerequisite only in conjunction with the pharmacodynamics. There are two different dose adjustment rules: proportional dose reduction according to Luzius Dettli, and the half dosage rule according to Calvin Kunin. The latter leads to higher trough concentrations but is probably more efficient for anti-infective therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959896      PMCID: PMC2956196          DOI: 10.3238/arztebl.2010.0647

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  44 in total

1.  The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis.

Authors:  A Schwarz; P H Krause; U Kunzendorf; F Keller; A Distler
Journal:  Clin Nephrol       Date:  2000-09       Impact factor: 0.975

2.  Persistence of antibiotics in blood of patients with acute renal failure. I. Tetracycline and chlortetracycline.

Authors:  C M KUNIN; S B REES; J P MERRILL; M FINLAND
Journal:  J Clin Invest       Date:  1959-09       Impact factor: 14.808

Review 3.  Oral phosphate binders in patients with kidney failure.

Authors:  Marcello Tonelli; Neesh Pannu; Braden Manns
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

Review 4.  Review on pharmacokinetics and pharmacodynamics and the aging kidney.

Authors:  Christian Aymanns; Frieder Keller; Sebastian Maus; Bertram Hartmann; David Czock
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

Review 5.  Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease.

Authors:  G F M Strippoli; S D Navaneethan; J C Craig
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

6.  Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy.

Authors:  Benjamin Boesler; David Czock; Frieder Keller; Martin Griesshammer; Thomas Seufferlein; Wolfram Karges; Franz Maximilian Rasche
Journal:  Nephrol Dial Transplant       Date:  2005-04-19       Impact factor: 5.992

7.  MESNA (sodium 2-mercaptoethanesulfonate) for prevention of contrast medium-induced nephrotoxicity - controlled trial.

Authors:  U Ludwig; M K Riedel; M Backes; A Imhof; R Muche; F Keller
Journal:  Clin Nephrol       Date:  2011-04       Impact factor: 0.975

8.  Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients.

Authors:  Andrea Corsonello; Claudio Pedone; Francesco Corica; Chiara Mussi; Pierugo Carbonin; Raffaele Antonelli Incalzi
Journal:  Arch Intern Med       Date:  2005-04-11

9.  Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval?

Authors:  David Czock; F M Rasche
Journal:  Eur J Med Res       Date:  2005-04-20       Impact factor: 2.175

10.  Renal failure occurs in chronic lithium treatment but is uncommon.

Authors:  Hans Bendz; Staffan Schön; Per-Ola Attman; Mattias Aurell
Journal:  Kidney Int       Date:  2009-11-25       Impact factor: 10.612

View more
  29 in total

1.  Dialysis after administration of gadolinium?

Authors:  Fedai Özcan
Journal:  Dtsch Arztebl Int       Date:  2011-02-18       Impact factor: 5.594

2.  Antithrombotic prophylaxis and therapy in renal failure.

Authors:  Carsten Kienitz; Ludger Rosin; W Dieter Paar
Journal:  Dtsch Arztebl Int       Date:  2011-02-18       Impact factor: 5.594

3.  Vote in favor of insulin.

Authors:  Günther Egidi
Journal:  Dtsch Arztebl Int       Date:  2011-02-18       Impact factor: 5.594

4.  The problems of empirical formulas.

Authors:  Helmut Nocke
Journal:  Dtsch Arztebl Int       Date:  2011-02-18       Impact factor: 5.594

5.  Anticoagulation in renal failure is safe and effective.

Authors:  Reinhard Klingel
Journal:  Dtsch Arztebl Int       Date:  2011-02-18       Impact factor: 5.594

Review 6.  [Antibiotic dosing for renal function disorders and continuous renal replacement therapy].

Authors:  Erik Michael; Detlef Kindgen-Milles
Journal:  Anaesthesist       Date:  2015-04       Impact factor: 1.041

7.  Suboptimal antimicrobial drug exposure in patients with renal impairment.

Authors:  David Czock; Martino Spitaletta; Frieder Keller
Journal:  Int J Clin Pharm       Date:  2015-05-28

8.  Kidney Function, Polypharmacy, and Potentially Inappropriate Medication Use in a Community-Based Cohort of Older Adults.

Authors:  Alex Secora; G Caleb Alexander; Shoshana H Ballew; Josef Coresh; Morgan E Grams
Journal:  Drugs Aging       Date:  2018-08       Impact factor: 3.923

Review 9.  [Pain therapy for Fabry's disease].

Authors:  C Sommer; N Uçeyler; T Duning; K Arning; R Baron; E Brand; S Canaan-Kühl; M Hilz; D Naleschinski; C Wanner; F Weidemann
Journal:  Internist (Berl)       Date:  2013-01       Impact factor: 0.743

10.  Polypharmacy and Renal Failure in Nursing Home Residents: Results of the Inappropriate Medication in Patients with Renal Insufficiency in Nursing Homes (IMREN) Study.

Authors:  Michael Dörks; Stefan Herget-Rosenthal; Guido Schmiemann; Falk Hoffmann
Journal:  Drugs Aging       Date:  2016-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.